Triple Hair Group

Triple Hair is a clinical-stage Canadian biotechnology company dedicated to developing and commercializing innovative therapies for hair loss. The company's flagship prescription candidate, TH07, is a patented topical formulation combining minoxidil, finasteride, and latanoprost, which has demonstrated superior efficacy in Phase 2 trials and is progressing toward Phase 3 for androgenetic alopecia. In addition to its pharmaceutical pipeline, Triple Hair offers over-the-counter brands like Plenty and RIZN, targeting both women and men with science-based hair growth solutions. Headquartered in Moncton, New Brunswick, the company leverages a multi-modal approach to address the complex biological pathways of hair follicle miniaturization. Triple Hair aims to redefine the standard of care in dermatology by providing more effective, synergistic alternatives to existing hair regrowth treatments.